ATE122893T1 - Vakzin gegen neisseria meningitidis gruppe-b, gammaglobulin und transferfaktor. - Google Patents

Vakzin gegen neisseria meningitidis gruppe-b, gammaglobulin und transferfaktor.

Info

Publication number
ATE122893T1
ATE122893T1 AT88500077T AT88500077T ATE122893T1 AT E122893 T1 ATE122893 T1 AT E122893T1 AT 88500077 T AT88500077 T AT 88500077T AT 88500077 T AT88500077 T AT 88500077T AT E122893 T1 ATE122893 T1 AT E122893T1
Authority
AT
Austria
Prior art keywords
protein
treatment
chromatography
mixture
neisseria meningitidis
Prior art date
Application number
AT88500077T
Other languages
German (de)
English (en)
Inventor
Huergo Concepcion Campa
Gonzalez Victoriano Gus Sierra
Vazquez Maria Merced Gutierrez
Jorrin Gonzalo Bisset
Imia Luis Guillermo Garcia
Rizo Gisela De La Cari Puentes
Herrera Maria Del Car Sampedro
Padron Franklin Sotolongo
Le Riverend Morales El Xochitl
Dominguez Manuel Alfr Galguera
Original Assignee
Nacional De Biopreparados Cent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nacional De Biopreparados Cent filed Critical Nacional De Biopreparados Cent
Application granted granted Critical
Publication of ATE122893T1 publication Critical patent/ATE122893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT88500077T 1987-07-30 1988-07-30 Vakzin gegen neisseria meningitidis gruppe-b, gammaglobulin und transferfaktor. ATE122893T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1987125 1987-07-30

Publications (1)

Publication Number Publication Date
ATE122893T1 true ATE122893T1 (de) 1995-06-15

Family

ID=5459411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88500077T ATE122893T1 (de) 1987-07-30 1988-07-30 Vakzin gegen neisseria meningitidis gruppe-b, gammaglobulin und transferfaktor.

Country Status (11)

Country Link
US (2) US5597572A (OSRAM)
EP (1) EP0301992B1 (OSRAM)
JP (1) JPH01125328A (OSRAM)
AT (1) ATE122893T1 (OSRAM)
AU (3) AU615461B2 (OSRAM)
CA (1) CA1341199C (OSRAM)
DE (1) DE3853854T2 (OSRAM)
ES (1) ES2074445T3 (OSRAM)
GR (1) GR3017218T3 (OSRAM)
IN (1) IN167607B (OSRAM)
RU (1) RU2023448C1 (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
DE68921895T3 (de) * 1988-12-19 2003-05-22 American Cyanamid Co., Portland Meningococcales klasse i-aussenmembranprotein-vakzin.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US6287574B1 (en) 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
RU2347813C2 (ru) * 1997-11-06 2009-02-27 Чирон С.П.А. Антигены нейссерий
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808734D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9811260D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
CN1344322A (zh) * 1999-01-22 2002-04-10 史密丝克莱恩比彻姆生物有限公司 脑膜炎奈瑟氏菌basb055多核苷酸和多肽及其用途
NZ528254A (en) 1999-05-19 2005-07-29 Chiron S Combined neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9929923D0 (en) * 1999-12-17 2000-02-09 Baldwin Thomas J Antigen preparations
EP1322328B1 (en) 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP2004529643A (ja) * 2001-04-17 2004-09-30 カイロン コーポレイション 機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
RU2355704C2 (ru) * 2001-04-17 2009-05-20 Новартис Вэксинс Энд Диагностикс, Инк Моноклональное антитело, направленное против gna33 пептида, и его применение
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
US20060034854A1 (en) 2002-08-02 2006-02-16 Berthet Francois-Xavier J Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
US20040241190A1 (en) * 2003-04-07 2004-12-02 Xenova Research Limited Vaccine preparations
RU2250113C2 (ru) * 2003-06-04 2005-04-20 Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова Российской академии наук Способ приготовления бивалентной вакцины для профилактики менингококковой инфекции
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23420A1 (es) * 2003-12-30 2009-09-08 Univ De Cambridge Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
PE20070123A1 (es) 2005-06-27 2007-02-08 Glaxosmithkline Biolog Sa Composicion inmunogenica
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US7943352B2 (en) * 2006-03-29 2011-05-17 Bacoustics, Llc Apparatus and methods for vaccine development using ultrasound technology
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
EP2114991A1 (en) * 2007-02-07 2009-11-11 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Recombinant antigens of human cytomegalovirus (hcmv)
EP2245048B1 (en) 2008-02-21 2014-12-31 Novartis AG Meningococcal fhbp polypeptides
CU20080215A7 (es) 2008-11-19 2012-06-21 Inst Finlay Vacunas unitemporales
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CU20100083A7 (es) 2010-05-05 2012-06-21 Inst Finlay Tolerogenos adyuvados como vacuna de malaria
KR101817450B1 (ko) 2010-08-23 2018-01-11 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
BR112013005329A2 (pt) 2010-09-10 2017-05-02 Wyeth Llc variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
CU20110202A7 (es) * 2011-11-02 2013-12-27 Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA3195971A1 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP2689775A1 (en) 2012-07-25 2014-01-29 Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros Cochleate with only one mamp
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
LT3110442T (lt) 2014-02-28 2020-12-28 Glaxosmithkline Biologicals Sa Modifikuoti meningokokinio fhbp polipeptidai
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3577130A2 (en) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis compositions and methods thereof
RU2659948C1 (ru) * 2017-03-14 2018-07-04 Федеральное государственное бюджетное научноеучреждение "Омский аграрный научный центр" (ФГБНУ "Омский АНЦ") Способ получения R-бруцеллёзной сыворотки на кроликах
CN110157767A (zh) * 2019-04-18 2019-08-23 金花企业(集团)股份有限公司 一种转移因子口服溶液生物活性测定方法
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4386066A (en) * 1981-08-20 1983-05-31 Merck & Co., Inc. Immunogenic complex from N. gonorrhoeae
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4885005A (en) * 1982-11-12 1989-12-05 Baxter International Inc. Surfactant treatment of implantable biological tissue to inhibit calcification
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4505853A (en) * 1983-11-18 1985-03-19 Ortho Pharmaceutical Corporation Enzyme-resistant immunomodulatory peptides
US4547489A (en) * 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US4629723A (en) * 1984-06-27 1986-12-16 Ortho Pharmaceutical Corporation Potent thymopentin analogs
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US4838888A (en) * 1987-04-17 1989-06-13 Baxter Travenol Laboratories, Inc. Calcification mitigation of implantable bioprostheses

Also Published As

Publication number Publication date
IN167607B (OSRAM) 1990-11-24
ES2074445T3 (es) 1995-09-16
DE3853854D1 (de) 1995-06-29
EP0301992A2 (en) 1989-02-01
AU5319794A (en) 1994-03-24
CA1341199C (en) 2001-03-06
US5597572A (en) 1997-01-28
EP0301992A3 (en) 1990-02-14
AU615461B2 (en) 1991-10-03
US5747653A (en) 1998-05-05
AU2031288A (en) 1989-05-25
EP0301992B1 (en) 1995-05-24
RU2023448C1 (ru) 1994-11-30
JPH01125328A (ja) 1989-05-17
GR3017218T3 (en) 1995-11-30
DE3853854T2 (de) 1996-02-08
AU8134991A (en) 1991-10-31

Similar Documents

Publication Publication Date Title
ATE122893T1 (de) Vakzin gegen neisseria meningitidis gruppe-b, gammaglobulin und transferfaktor.
Une et al. Roles of V antigen in promoting virulence and immunity in yersiniae.
FI104539B (fi) Menetelmä muunnellun Neisseria meningitidis ryhmä B polysakkaridin tai muunnellun E. coli K1 kotelomaisen polysakkaridin valmistamiseksi
US5811102A (en) Modified meningococcal polysaccharide conjugate vaccines
LV12309A (lv) Pneimokoku polisaharidus saturosa vakcina
ATE127345T1 (de) Stressproteine und verwendungen dafür.
CN1060408A (zh) 改进的疫苗组合物
DE3751588D1 (de) Verfahren zum Verringern der Toxizität von LPS und Verfahren zum Dezoxifizieren eines LPS-haltigen flüssigen therapeutischen Mittels.
NO975546D0 (no) Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav
JPH05246890A (ja) グラム陰性菌トキソイドにより得られる免疫グロブリン
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
Jarrett et al. Antibody response and virus survival in cats vaccinated against feline leukaemia
JPH01502190A (ja) インフルエンザ菌用ワクチンおよび診断法
USRE37741E1 (en) Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection
DK0565590T3 (da) Adhesin-oligosaccharid-konjugatvaccine mod Haemophilus influenzae
DK172253B1 (da) Tumorterapeutikum, fremgangsmåde til dets fremstilling samt anvendelse af humane tumorceller til fremstilling af et terapeutikum til behandling af tumorlidelser
JPH01190635A (ja) 抗体およびそれを有効成分とするう蝕予防剤、並びにこれらの製造方法
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
JP3135060B2 (ja) ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体
Karakawa et al. Immunochemical analysis of a Smith-like antigen isolated from two human strains of Staphylococcus aureus
Gilbert et al. Purification of type 5 capsular polysaccharide from Straphylococcus aureus by a simple efficient method
WO1990013660A2 (en) Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
PT87001A (pt) Processo para a preparacao de uma vacina contra a disenteria suina e fins analogos
US6248563B1 (en) Chlamydia trachomatis serotype D genes
PT85248A (fr) Procede d:isolement d:un peptide presentant des proprietes antigeniques isole de la proteine 28kd de ?s.mansoni?,anticorps monoclonaux reconnaissant au moins un epitope dudit peptide et applications de celui-ci dans l:induction de la synthese d:anticorps neutralisants

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time